Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Decreased circulating vitamin B12 concentration, Folate-responsive megaloblastic anemia, Schistocytosis, and Hyperbilirubinemia and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 3 | Folate-responsive megaloblastic anemia, Episodic hemolytic anemia, Hypersegmentation of neutrophil nuclei |
SLC19A1 function has not been fully characterized.
Megaloblastic anemia, folate-responsive is associated with mutations in the SLC19A1 gene on chromosome 21.
No consensus clinical diagnostic criteria for SLC19A1-related folate transport deficiency (SLC19A1-FTD) have been published.
SLC19A1-FTD should be suspected in untreated probands with the following clinical, supportive laboratory, and imaging findings and family history.
Clinical findings
Birth weight and head circumference that are in the lower ranges of the typical growth chart for age and sex
No approved treatments are currently available for megaloblastic anemia, folate-responsive. The disease remains an area of unmet medical need.
Gene therapy approaches for megaloblastic anemia, folate-responsive have been reported in the published literature.
No clinical practice guidelines for SLC19A1-related folate transport deficiency (SLC19A1-FTD) have been published. In the absence of published guidelines, the following recommendations are based on reported treatment of other folate transport disorders that result in systemic and/or cerebral folate deficiency.
To monitor existing manifestations, the individual's response to targeted therapy and supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 6. SLC19A1-Related Folate Transport Deficiency: Recommended Surveillance
No clinical trials have been registered for megaloblastic anemia, folate-responsive.
65 publications have been identified in PubMed for megaloblastic anemia, folate-responsive. Research spans Epidemiology / Natural History (52%), Basic Science / Preclinical (15%), and Diagnostic / Biomarker (12%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 34 | 52% |
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 9:40 AM UTC
Online Mendelian Inheritance in Man
Lab test results |
3 |
Hyperbilirubinemia, Elevated LDH (tissue damage marker) (increased circulating lactate dehydrogenase concentration), Elevated ferritin (iron storage marker) (increased circulating ferritin concentration) |
Age of onset: adulthood.
SLC19A1 encodes the reduced folate carrier (RFC) protein that mediates transport of folates into mammalian cells. The clinical findings associated with SLC19A1-related folate transport deficiency (SLC19A1-FTD) depend on the degree of RFC functional loss associated with the pathogenic variants . With severe deficiency, signs may be present at or shortly after birth . With modest loss of function, clinical manifestations may be delayed and only emerge when dietary folate intake is insufficient . When the sole manifestations are hematologic, immunologic/infectious, and/or gastrointestinal, treatment with folate can completely reverse these signs and symptoms. Developmental and neurologic findings may improve with treatment depending on the extent and duration of impairment and adequacy of treatment (see Management, ). To date, five individuals from three families have been identified with biallelic pathogenic variants in SLC19A1 . In addition, two sibs died at an early age prior to diagnosis . The following description of the phenotypic features associated with this condition in untreated individuals is based on these reports. Table 2. SLC19A1-Related Folate Transport Deficiency: Frequency of Select Features in Untreated Individuals
Feature | Proportion of Persons w/Feature1 | Comment |
|---|---|---|
Megaloblastic anemia | 5/5 | — |
Recurrent infections | 4/5 | Most commonly respiratory |
Leukopenia /or thrombocytopenia | 4/5 | — |
Low immunoglobulin levels | 4/5 | — |
Mucositis (oral lesions) diarrhea | 4/5 | — |
Delayed myelination, cerebral/cerebellar calcifications on brain MRI | 3/3 | MRIs obtained in 3 persons only |
Developmental delay/ intellectual disability | 4/5 | — |
Seizures | 1/5 | Four of the five affected individuals had pathogenic variants predicted to cause a marked loss of RFC function. One affected individual, for whom the only manifestation was late-onset anemia, had a pathogenic variant predicted to cause only mild loss of protein function. Hematologic findings. |
Source: GeneReviews — "SLC19A1-Related Folate Transport Deficiency"
Poor postnatal growth
Developmental delay, including gross motor (gait), speech/language, and cognitive skills
Seizures
Recurrent infections, particularly respiratory
Mucositis with oral lesions
Diarrhea
Supportive laboratory findings
Anemia, typically megaloblastic, that may be accompanied by leukopenia and/or thrombocytopenia
Normal blood folate with low red blood cell folate
Source: GeneReviews — "SLC19A1-Related Folate Transport Deficiency"
Impaired function of folate transporters. There are three inherited disorders due to impaired function of folate transporters: SLC19A1-related folate transport deficiency (SLC19A1-FTD; the topic of this GeneReview), hereditary folate malabsorption (HFM), and FOLR1-related cerebral folate transport deficiency (FOLR1-CFTD). Although all three disorders can result in developmental, cognitive, and neurologic defects, the clinical characteristics and laboratory findings reflect the affected transporter's unique role in folate physiology.
Source: GeneReviews — "SLC19A1-Related Folate Transport Deficiency"
Genetic testing for SLC19A1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for megaloblastic anemia, folate-responsive has been reported in the published literature.
To establish the extent of disease and needs in an individual diagnosed with SLC19A1-FTD, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
SLC19A1-Related Folate Transport Deficiency: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Obtain the following:
Serum RBC folate concentrations
Serum total homocysteine concentration
| To assess for degree of metabolic abnormality
| CSF folate level | As a baseline to aid in determining appropriate folate dosing
Baseline brain MRI | • To delineate if there are any brain abnormalities incl delayed myelination cerebral cerebellar calcifications
May be used over time as indication of adequacy of CSF folate concentrations achieved
Neurologic eval | Consider EEG if seizures are a concern.
| CBC w/peripheral smear indices | To assess for macrocytic anemia /or pancytopenia
Consider bone marrow exam in those w/pancytopenia. | To evaluate for other causes or a secondary diagnosis that could lead to pancytopenia
| Quantitative assessment of serum immunoglobu...
Source: GeneReviews — "SLC19A1-Related Folate Transport Deficiency"
View trials for megaloblastic anemia, folate-responsive
Evaluation |
|---|
Frequency |
|---|
Metabolic | Obtain serum RBC folate concentrations1 total homocysteine concentration. | Once corrected, monitor every 3 mos for 2 yrs every 6 mos thereafter, if stable. |
Neurologic | Monitor CSF folate concentrations. | CSF folate determinations will be required until levels are above those normal for age.2; Monitor periodically thereafter, if possible, for the 1st 5 yrs, if there are progressive developmental or neurologic signs or concerns about adherence. |
Hematologic | CBC | Once corrected, monitor every 3 mos for 2 yrs every 6 mos thereafter, if stable. |
Immunologic | Serum immunoglobulin levels if there are hematologic findings or recurrent infections3 | Once immunoglobulins are normalized, they need not be repeated as long as hematologic metabolic parameters are normal stable. Developmental/ |
Cognitive | Monitor developmental progress educational needs. | At each visit CBC = complete blood count; RBC = red blood cell Folate blood levels must be supranormal to compensate for SLC19A1-FTD, the extent to which will depend on the severity of the transport defect. |
Source: GeneReviews — "SLC19A1-Related Folate Transport Deficiency"
Phenotype severity distribution: 10 always present features.
Laboratory research
10 |
15% |
Testing and diagnosis research | 8 | 12% |
Research summaries | 7 | 11% |
Patient case studies | 3 | 5% |
Other research | 1 | 2% |
Clinical study results | 1 | 2% |
New treatment approaches | 1 | 2% |
Mostert CQB (2026). [PMID: 41763665](https://pubmed.ncbi.nlm.nih.gov/41763665/). *BMJ case reports*. [Case Report / Case Series]
Wang T (2026). [PMID: 41355145](https://pubmed.ncbi.nlm.nih.gov/41355145/). *Molecular nutrition & food research*. [Epidemiology / Natural History]
Allemand A (2026). [PMID: 42130936](https://pubmed.ncbi.nlm.nih.gov/42130936/). *Eur J Case Rep Intern Med*. [Case Report / Case Series]
Ghosh SK (2026). [PMID: 41692080](https://pubmed.ncbi.nlm.nih.gov/41692080/). *Clinics in dermatology*. [Review / Meta-Analysis]
de Castro MM (2026). [PMID: 41896411](https://pubmed.ncbi.nlm.nih.gov/41896411/). *European journal of clinical nutrition*. [Basic Science / Preclinical]
Al-Taiar A (2026). [PMID: 41919344](https://pubmed.ncbi.nlm.nih.gov/41919344/). *Br J Nutr*. [Epidemiology / Natural History]
Ding X (2026). [PMID: 41742118](https://pubmed.ncbi.nlm.nih.gov/41742118/). *BMC pregnancy and childbirth*. [Epidemiology / Natural History]
Zeng W (2026). [PMID: 41824854](https://pubmed.ncbi.nlm.nih.gov/41824854/). *Medicine*. [Epidemiology / Natural History]
Geng H (2026). [PMID: 41710151](https://pubmed.ncbi.nlm.nih.gov/41710151/). *International journal of women's health*. [Basic Science / Preclinical]
Datta Mitra A (2026). [PMID: 41754181](https://pubmed.ncbi.nlm.nih.gov/41754181/). *Nutrients*. [Review / Meta-Analysis]